BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that it has introduced its MGMT gene methylation assay using Methylation-Specific PCR technology licensed from OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA). Methylation of the MGMT gene promoter has been shown to be a common event in brain cancers and predictive of response to some therapies.
